{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-019127","form_type":"8-K","ticker":null,"cik":"0001840748","company_name":"LAVA Therapeutics NV","filed_at":"2025-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.220620+00:00","generated_at":"2026-05-26T00:02:05.414631+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LAVA Therapeutics receives Nasdaq deficiency notice; shares below $1.00 for 30 days","bullets":["Nasdaq notified LAVA on Feb 27, 2025, that its common shares failed to meet the $1.00 minimum bid price for 30 consecutive business days.","Company has 180 days, until Aug 26, 2025, to regain compliance by closing at $1.00+ for 10 consecutive trading days.","Failure could lead to transfer to Nasdaq Capital Market for an additional 180-day cure period if eligibility criteria are met.","LAVA will monitor bid price and consider available options; no assurance of regaining compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-019127","json":"https://secwatch.observer/filing/0001104659-25-019127.json","markdown":"https://secwatch.observer/filing/0001104659-25-019127.md","text":"https://secwatch.observer/filing/0001104659-25-019127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840748/000110465925019127/0001104659-25-019127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840748/000110465925019127/tm257957d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T00:02:05.414631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67dd56a02b44336351c28d892dd9e9dc0d97e562","claim":"LAVA Therapeutics NV received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"February 27, 2025, LAVA Therapeutics N.V. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common shares has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common shares on The Nasdaq Global Select Market. The Company has 180 calendar days, or until August 26, 2025, to regain compliance with the minimum bid price requirement. To regain com","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840748/000110465925019127/0001104659-25-019127-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}